COMMUNIQUÉS West-GlobeNewswire

60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis
26/05/2026
Enrollment is tracking ahead of schedule, allowing potential acceleration of key trial milestones Minimum enrollment to support interim analysis expected as soon as early July 2026 Randomized, double-blind, placebo- [...]
Clearmind Medicine Announces Johns Hopkins IRB Approval to Advance CMND-100 Phase I/II Clinical Trial to the Next Parts
26/05/2026
Vancouver, Canada, May 26, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non- [...]
AiM Medical Robotics Announces Collaboration Agreement with Siemens Healthineers to Advance MRI-Guided Robotic Neurosurgery
26/05/2026
Worcester, MA, May 26, 2026 (GLOBE NEWSWIRE) -- AiM Medical Robotics, a leading developer of advanced robotic systems for MRI-guided neurosurgery, today announced a collaboration agreement with Siemens Healthineers for [...]
Microbot Medical® Receives Its First International Regulatory Approval for the Commercialization of the LIBERTY® Endovascular Robotic System
26/05/2026
Israel becomes the second jurisdiction and the first outside of the U.S. to grant marketing clearance for the LIBERTY System The AMAR regulatory approval will enable the Company to obtain a Free Sale Certificate to [...]
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
26/05/2026
SOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for [...]
RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting
26/05/2026
Sub-Study from Ongoing Phase III TIGeR-PaC Clinical Trial Supports TAMP for Targeted Intra-Arterial Delivery of Gemcitabine, Demonstrating Potential to Increase Local Drug Potency and Reduce Systemic Exposure and Common [...]
Silexion Therapeutics Announces 1-for-10 Reverse Share Split
26/05/2026
Trading on split-adjusted basis will begin at market open on May 29, 2026. This adjustment is expected to help Silexion comply with Nasdaq requirements, enhance its market position, and support its progress in [...]
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
26/05/2026
CLEVELAND, May 26, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in June 2026: 2026 Jefferies [...]
Santhera’s Shareholders Approve all Board Proposals at Today’s Annual General Meeting
26/05/2026
Pratteln, Switzerland, May 26, 2026 – Santhera Pharmaceuticals (SIX: SANN) today announces that its shareholders approved all motions by the Board of Directors at the Annual General Meeting (AGM) held today in Pratteln [...]
Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering
26/05/2026
CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the pricing of an [...]
PacBio SPRQ-Nx Chemistry Now Shipping Worldwide, Enabling Sub-$300 HiFi Genomes for Large Scale Projects and AI-Enhanced Sequencing
26/05/2026
New Revio multi-use SMRT Cells reduce sequencing costs by 30% compared to previous SPRQ chemistry while DeepConsensus improvements and expanded methylation calling increase accuracy, yield, and epigenetic insight MENLO [...]
Catalyst MedTech Unveils Expanded Digirad® Portfolio, Imaging Innovation Showcase, and Long-Term Support Strategy at SNMMI 2026
26/05/2026
Expanded OEM portfolio, modernization initiatives, and collaborative innovation experiences position Catalyst MedTech as a leading partner for nuclear medicine and molecular imaging providers nationwide PITTSBURGH, May [...]
MEDX HOLDINGS (MEDH) REPORTS EXCEPTIONAL Q1 2026 FINANCIALS: REVENUE SURGES, EXPANSION ON TRACK, AND CEO TO SPEAK AT HEMP BEVERAGE EXPO
26/05/2026
MedX Holdings and the Lazydaze franchise momentum keeps building - The New Era After Cannabis Rescheduling Austin, Texas , May 26, 2026 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE MEDX HOLDINGS (MEDH) REPORTS EXCEPTIONAL [...]
Cosmos Health Releases 2026–2029 Guidance: Targeting $200M Revenue, $71M Gross Profit, and $44M Adjusted EBITDA by 2029 — Building an Innovative, High-Margin Healthcare Platform with Strong Cash Generation
26/05/2026
Revenue increasing 207% at a 32% CAGR: From $65.3 million in 2025 to $200.6 million by 2029, driven by strong growth across all core segments Gross profit growing 801% to $71.2M: Margins expanding from 12.1% to 35.5% — [...]
Transactions in connection with share buy-back program
26/05/2026
Company announcement no. 18 - 26 26 May 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Trading in GN Store Nord shares by board members, executives and associated persons
26/05/2026
GN Store Nord has received notification pursuant to article 19 of regulation (EU) no. 596/2014 of the below transactions related to shares in GN Store Nord made by persons discharging managerial responsibilities in GN [...]
Novo Nordisk global observational study reveals 2 in 5 people with cardiovascular disease have cardiovascular inflammation, increasing their risk of heart attack and stroke
26/05/2026
The Novo Nordisk study POSEIDON – including 18,904 patients across 18 countries - showed that cardiovascular (CV) inflammation remains highly prevalent among people with cardiovascular disease (CVD), despite current [...]
New study finds over a third of young men at risk of gambling related harm; fathers disproportionately affected
26/05/2026
VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- Facing economic and financial pressure, new research shows that young men and fathers are at significantly higher risk of problem gambling. This may be [...]
Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress
26/05/2026
Single dose of EDIT-401 achieved ~90% or greater mean reductions in LDL-C, Lp(a), and ApoB in non-human primates Data reinforce differentiated LDLR upregulation approach with rapid, dose-dependent effects on multiple [...]

Pages